Mr Driscoll most recently served as Genelabs’s CFO and has been sharing CEO responsibilities with Irene Chow, the company’s executive chairman. He has more than 30 years of financial management and operational leadership experience in the biotechnology and medical device industries.
Prior to joining Genelabs he was employed by Oxigene, initially as vice president of finance and operations and subsequently as president and CEO. Previously, Mr Driscoll served as senior vice president of finance and operations for Collagenesis and as vice president of finance for Instrumentation Laboratory.